Large vessel occlusion thrombectomy procedures are being used in medium vessel occlusions, leading to changes in device ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

"Okami secures $45m to advance clinical programmes for vascular disease" was originally created and published by Medical Device Network, a GlobalData owned brand.

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

A new study published in The American Journal of Cardiology revealed acute total occlusion (ATO) in non-ST-segment elevation ...

A new study published in the Journal of American Medical Association showed that subcutaneous nitroglycerin demonstrated ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...